Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction

Marasco, Silvana F.; Pilcher, David; Oto, Takahiro; Chang, Wenly; Griffiths, Anne; Pellegrino, Vince; Chan, Justin; Bailey, Michael
February 2010
European Journal of Cardio-Thoracic Surgery;Feb2010, Vol. 37 Issue 2, p420
Academic Journal
Abstract: Objective: Aprotinin has been widely used to reduce bleeding and transfusion requirements in cardiac surgery and in lung transplantation. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been used. However, recently, concerns regarding the safety of aprotinin have been raised, and the future use of aprotinin is uncertain. In our institution, aprotinin has been widely used in cardiac surgery and transplantation. We decided to review our lung transplant caseload to investigate the impact of aprotinin on PGD and mortality and to guide our future clinical use of this antifibrinolytic. Methods: A retrospective review of prospectively collected data on 213 consecutive patients who underwent single- or double-lung transplantation was performed. Ninety-nine patients, who received aprotinin, were compared with 114 patients who did not. The main outcome variables analysed were development of primary graft dysfunction, renal impairment and mortality. Results: Aprotinin was associated with a significantly increased risk of PGD in the first 48h postoperatively (p =0.01). Conclusions: In conclusion, although the benefits of aprotinin on blood loss are well established, this study does not provide support for the use of aprotinin to reduce PGD in lung transplantation and indicates that aprotinin may in fact have a detrimental effect.


Related Articles

  • Fibrinolýza v kardiochirurgii v postaprotinínovej ére. Ján, Špegár; Petra, Pazderková; Tomáš, Vaněk // Anaesthesiology & Intensive Medicine / Anesteziologie a Intenziv;Oct2011, Vol. 22 Issue 5, p260 

    The use of antifibrinolytics for prevention of massive haemorrhagic events and deterioration during the perioperative course of a patient is a routine practice in many cardiac centres nowadays. Following the with - drawal of the most powerful antifibrinolytic agent aprotinin, attention of the...

  • Safety of antifibrinolytic therapy during cardiac surgery and randomized controlled trials. Koster, A.; Zittermann, A.; Schirmer, U. // BJA: The British Journal of Anaesthesia;Jun2013, Vol. 110 Issue 6, p1055 

    No abstract available.

  • Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery Schindler, Ehrenfried; Photiadis, Joachim; Sinzobahamvya, Nicodème; Döres, Albert; Asfour, Boulos; Hraska, Victor // European Journal of Cardio-Thoracic Surgery;Apr2011, Vol. 39 Issue 4, p495 

    Abstract: Objective: There has been concern about the usage of aprotinin, an antifibrinolytic drug that was often used in pediatric cardiac surgery until 2006. At our center, these concerns led to the replacement of aprotinin with tranexamic acid for antifibrinolytic treatment. Methods: In this...

  • Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial Later, Alexander F.L.; Maas, Jacinta J.; Engbers, Frank H.M.; Versteegh, Michel I.M.; Bruggemans, Eline F.; Dion, Robert A.E.; Klautz, Robert J.M. // European Journal of Cardio-Thoracic Surgery;Aug2009, Vol. 36 Issue 2, p322 

    Abstract: Objective: Tranexamic acid has been suggested to be as effective as aprotinin in reducing blood loss and transfusion requirements after cardiac surgery. Previous studies directly comparing both antifibrinolytics focus on high-risk cardiac surgery patients only or suffer from...

  • Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Grassin-Delyle, S.; Tremey, B.; Abe, E.; Fischler, M.; Alvarez, J. C.; Devillier, P.; Urien, S. // BJA: The British Journal of Anaesthesia;Dec2013, Vol. 111 Issue 6, p916 

    Background Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either low- or...

  • The Safety and Efficacy of Antifibrinolytic Therapy in Neonatal Cardiac Surgery. Lin, Chih-Yuan; Shuhaiber, Jeffery H.; Loyola, Hugo; Liu, Hua; del Nido, Pedro; DiNardo, James A.; Pigula, Frank A. // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Neonates undergoing open-heart surgery are particularly at risk of postoperative bleeding requiring blood transfusion. Aprotinin has attained high efficacy in reducing the requirement for a blood transfusion following a cardiopulmonary bypass, but is seldom studied in the neonatal...

  • P229 Tranexamic acid and aprotinin: antifibrinolytics in cardiac surgery. Nemeth, BT; Hidi, L; Toth, R; Veres, G; Olah, A; Matyas, C; Merkely, G; Merkely, B; Szabo, G; Radovits, T // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS41 

    Purpose: Anti-haemorrhagic drugs are being used to prevent and treat haemorrhagic complications in cardiac surgery. The serine-protease-inhibitor aprotinin is an antifibrinolytic agent that had been used in clinical practice for decades. In 2008, the BART-study revealed its unfavourable effects...

  • Involvement of E-cadherin cleavage in reperfusion injury Goto, Taichiro; Ishizaka, Akitoshi; Katayama, Masahiko; Kohno, Mitsutomo; Tasaka, Sadatomo; Fujishima, Seitaro; Kobayashi, Koichi; Nomori, Hiroaki // European Journal of Cardio-Thoracic Surgery;Feb2010, Vol. 37 Issue 2, p426 

    Abstract: Objective: E-cadherin is a major cell-to-cell adhesion molecule, of which the ectodomain is cleaved from epithelial cells to yield a soluble form after the pathological alteration of the alveolar epithelium. We investigated the excretion level of soluble E-cadherin in a rat lung...

  • A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects. Ortolano, Girolamo A.; Aldea, Gabriel S.; Lilly, Kevin; O'Gara, Paul; Alkon, Joseph D.; Madera, Frederick; Murad, Tarek; Altenbern, Charles P.; Tritt, Charles S.; Capetandes, Anthony; Gikakis, Nicolas S.; Wenz, Barry; Shemin, Richard J.; Downey III, Francis X. // Perfusion;May2002 Supplement 1, Vol. 17, p53 

    Describes the time course of reperfusion injury that facilitates the study of anti-inflammatory effects of leukofiltration in cardiac surgery. Description of a systemic inflammatory response syndrome; Reduction of leucocytes using filtration; Pathogenesis of reperfusion injury.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics